Sociedad Americana de Hirudoterapia

Cardiopulmonary Bypass Without Heparin.

Review published in Seminars in cardiothoracic and vascular anesthesia (2016)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewEnsayos clínicosDesarrollo de fármacosRehfeldt et al. · Seminars in cardiothoracic and vascular anesthesia, 2016

Abstract

Due to familiarity, short half-life, ease of monitoring, and the availability of a reversal agent, heparin remains the anticoagulant of choice for cardiac operations requiring cardiopulmonary bypass (CPB). However, occasionally patients require CPB but should not receive heparin, most often because of acute or subacute heparin-induced thrombocytopenia (HIT). In these cases, if it is not feasible to wait for the disappearance of HIT antibodies, an alternative anticoagulant must be selected. A number of non-heparin anticoagulant options have been explored. However, current recommendations suggest the use of a direct thrombin inhibitor such as bivalirudin. This review describes the use of heparin alternatives for the conduct of CPB with a focus on the direct thrombin inhibitors.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsCardiopulmonary BypassHeparinHumansPerioperative CareThrombinThrombocytopenia

Resumen

Due to familiarity, short half-life, ease of monitoring, and the availability of a reversal agent, heparin remains the anticoagulant of choice for cardiac operations requiring cardiopulmonary bypass (CPB). However, occasionally patients require CPB but should not receive heparin, most often because...

Por qué esto importa para la hirudoterapia

This review examines alternative anticoagulants to heparin for cardiopulmonary bypass, focusing on direct thrombin inhibitors such as bivalirudin for patients who cannot receive heparin (e.g., due to heparin-induced thrombocytopenia). The discussion of direct thrombin inhibitors is tangentially relevant to ASH's domain because hirudin, the archetypal leech-derived anticoagulant, shares the same drug class and mechanistic lineage. However, the article does not mention leeches, hirudin, or hirudotherapy at all, and its clinical scope (cardiac surgery anticoagulation) is far removed from leech therapy applications. Relevance is therefore purely conceptual and indirect — it provides background on the pharmacological family to which a leech-derived compound belongs.

Citación

Cardiopulmonary Bypass Without Heparin.

Rehfeldt et al. · Seminars in cardiothoracic and vascular anesthesia, 2016

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.